G. Scott

Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation

A. Murphy, G. Yancopoulos, N. Stahl, 2019, Allergy.

IL-33 blockade impacts mediators of persistence and exacerbation in a model of chronic airway inflammation.

A. Murphy, G. Yancopoulos, N. Stahl, 2019, The Journal of allergy and clinical immunology.

Blocking common γ chain cytokine signaling ameliorates T cell–mediated pathogenesis in disease models

Kaitlyn M. Gayvert, A. Murphy, G. Yancopoulos, 2023, Science Translational Medicine.

IL-4 and IL-13, not eosinophils, drive type 2 airway inflammation, remodeling and lung function decline.

Johnathon R. Walls, A. Murphy, G. Yancopoulos, 2022, Cytokine.

Broader Impact of IL-4Rα Blockade than IL-5 Blockade on Mediators of Type 2 Inflammation and Lung Pathology in a House Dust Mite-Induced Asthma Mouse Model

A. Murphy, M. Sleeman, J. Orengo, 2019, C93. MECHANISMS OF AIRWAY INFLAMMATION IN ASTHMA AND COPD.

Blocking IL-4Ra with dupilumab prevents lung inflammation in a mouse asthma model

A. Murphy, M. Sleeman, Yu Bai, 2018, Airway Cell Biology and Immunopathology.

Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation

A. Murphy, M. Sleeman, Yu Bai, 2020 .